StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Trimebutine

HCID 5573
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
39133-31-8
Standard-SMILES
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C
InChIKey
LORDFXWUHHSAQU-UHFFFAOYSA-N
Summenformel
C22H29NO5
Durchschnittliche Molmasse
387,5 g/mol
Monoisotopische Masse
387,20457303

Überblick

3,4,5-trimethoxybenzoic acid [2-(dimethylamino)-2-phenylbutyl] ester is a trihydroxybenzoic acid.

Namen und Bezeichner

Bevorzugter Name
Trimebutine
IUPAC
[2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate
Englischer Name
Trimebutine
Summenformel
C22H29NO5
Molmasse
387.47

Namen und Synonyme

trimebutine39133-31-8TrimebutinumTrimebutina2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoateTransacalmModulon2-Dimethylamino-2-phenylbutyl 3,4,5-trimethoxybenzoatQZ1OJ92E5RMaleate, TrimebutineMaleate Salt, TrimebutineSalt, Trimebutine Maleate
Weitere Namen anzeigen
3,4,5-TRIMETHOXYBENZOIC ACID 2-[DIMETHYLAMINO]-2-PHENYLBUTYL ESTERMebutinTRIMEBUTINAPI Trimebutinetrimebutine free baseTrimebutine USP/EP/BPTrimebutine hydrochlorideTRIMEBUTINE 0.787% GRANULESCholesterol hemisuccinate Tris salt
DTXSID4023707(+-)-TrimebutineRefChem:389346DTXCID503707A03AA05TM906254-309-2Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester

Datenbank-Bezeichner

CAS
39133-31-8、58997-89-0、58997-90-3

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
4
Polarare Oberfläche (TPSA)
57,2 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
6
Frei drehbare Bindungen
10
Schwere Atome
28
Formalladung
0
Komplexität
466

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceutical
SolubilityInsoluble
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point78-82
Collision Cross Section193.19 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
78 · 78-80°C
Siedepunkt
513.42 °C · 513.42°C (rough estimate)
Dichte
1.1998 · 1.1998 (rough estimate)
Brechungsindex
1.5614 · 1.5614 (estimate)
storage temp.
2 · 2-8°C
Löslichkeit
Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Very Slightly)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 61.5% (8 of 13) of all reports.

Warning

H302 (23.1%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 13 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory Information · 2 Einträge

Chemical: Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester

REACH registered substance: Trimebutine (EC: 254-309-2)

Hazard Classes and CategoriesAcute Tox. 4 (23.1%)

Toxikologische Informationen

Drug Induced Liver Injury · 4 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Trimebutine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Sicherheitsdaten

wgk
3
hs_code
2922.19.0900
Speicherklasse
11 - Combustible Solids

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingProtein binding is minimal with 5% in vivo and in vitro to serum albumin.
Pharmacodynamics · 1 Eintrag

Trimebutine is a spasmolytic agent that acts directly on smooth muscle to modulate gastric motility. It shows a "dual function" that stimulates or inhibits spontaneous contractions depending on the concentration and prior contractile activity in the preparation. Targeting ion conductance that regulates GI motility, trimebutine inhibits the inward calcium currents and calcium-dependent potassium currents in a concentration-dependent manner. At lower concentrations (1-10uM), trimebutine depolarizes the resting membrane potential without affecting the amplitude of contractions, which is thought to be mediated by inhibition of outward potassium currents. It is also shown to activate T-type Ca2+ channel and increase gastric emptying, intestinal and colonic contractility. At higher concentrations (100-300uM), reduced amplitude of spontaneous contractions and action potentials is thought to be mediated by inhibition of L-type Ca2+ channels and inward calcium current. Trimebutine mediates a local anesthetic action by acting as a weak agonist at mu opioid receptors.

Mechanism of Action · 1 Eintrag

At high concentrations, trimebutine is shown to inhibit the extracellular Ca2+ influx in the smooth muscle cells through voltage dependent L-type Ca2+ channels and further Ca2+ release from intracellular Ca2+ stores. Trimebutine is suggested to bind to the inactivated state of the calcium channel with high affinity. Reduced calcium influx attenuates membrane depolarization and decrease colon peristalsis. It also inhibits outward K+ currents in response to membrane depolarization of the GI smooth muscle cells at resting conditions through inhibition of delayed rectifier K+ channels and Ca2+ dependent K+ channels, which results in induced muscle contractions. Trimebutine binds to mu opioid receptors with more selectivity compared to delta or kappa opioid receptors but with lower affinity than their natural ligands. Its metabolites (N-monodesmethyl-trimebutine or nor-trimebutine), are also shown to bind to opoid receptors on brain membranes and myenteric synaptosomes.

Zugehörige Reaktionen

2
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1445952
HRID 1445952als Edukt
Reaktionsgleichung von HRID 1879077
HRID 1879077als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
PubChem CID
5573
DTXSID
DTXSID4023707
ChEMBL
CHEMBL190044
ChEBI
CHEBI:94458
UNII
9RKX7S7WFY、QZ1OJ92E5R、U4UUZ24TRB
EC Number
254-309-2、261-548-6
Nikkaji
J15.812G、J304.096H、J304.097F
Aggregatzustand
Solid
pka
7.29 · 7.29±0.50(Predicted)
Farbe
White to Off-White
Wasserlöslichkeit
10 g/L · 10g/L
Merck
14 · 14,9699
Major Application
forensics and toxicologypharmaceutical (small molecule)veterinary
InChI
1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3
InChIKey
LORDFXWUHHSAQU-UHFFFAOYSA-N
SMILES
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c2ccccc2
CAS Datenbank
39133 · 39133-31-8(CAS DataBase Reference)
Biological Half-LifeThe elimination half life is approximately 1 hour following a single oral dose of 2mg/kg, and 2.77 hours following a single oral dose 200 mg.
Metabolism/Metabolites · 1 Eintrag

Trimebutine undergoes extensive hepatic first-pass metabolism. Nortrimebutine, or N-monodesmethyltrimebutine, is the main metabolite that retains pharmacological activity on the colon. This metabolite can undergo second N-demethylation to form N-didesmethyltrimebutine. Other main urinary metabolites (2-amino, 2-methylamino or 2-dimethylamino-2-phenylbutan-1-ol) can be formed via hydrolysis of the ester bond of desmethylated metabolites or initial hydrolysis of the ester bond of trimebutine followed by sequential N-demethylation. Trimebutine is also prone to sulphate and/or glucuronic acid conjugation.

MeSH Pharmacological Classification · 2 Einträge

Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.

Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.

Absorption, Distribution and Excretion · 3 Einträge

The free base form or salt form of trimebutine are rapidly absorbed after oral administration, with the peak plasma concentration reached after 1 hour of ingestion. The time to reach peak plasma concentration following a single oral dose of 200mg trimebutine is 0.80 hours.

Renal elimination is predominant while excretion into feces is also observed (5-12%). About 94% of an oral dose of trimebutine is eliminated by the kidneys in the form of various metabolites and less than 2.4% of total ingested drug is recovered as unchanged parent drug in the urine.

Trimebutine is most likely to be accumulated in the stomach and the intestinal walls in highest concentrations. The fetal transfer is reported to be low.

Anwendungen

VerwendenTrimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

2-Amino-2-phenylbuttersure